Physician profile
Sadia Chohan
NPI 1306890074
$13,365.29
in general payments reported to CMS, 2019-2025
78 companies · $3,459 in 2025
The $3,459 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $881 · 2021: $1,551 · 2022: $1,866 · 2023: $2,116 · 2024: $2,494 · 2025: $3,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,186.44 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $602.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,244.51 | 2019-2025 | |
| Pfizer INC. | $1,351.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $779.53 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $596.05 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $551.20 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $431.38 | 2019-2025 | Lunsumio, Polivy, Columvi |
| E.R. Squibb & Sons, L.L.C. | $399.51 | 2019-2025 | Opdivo, Eliquis |
| Genzyme Corporation | $357.72 | 2019-2025 | |
| Eisai INC. | $343.15 | 2020-2025 | |
| Abbvie INC. | $327.08 | 2019-2025 | |
| Array Biopharma INC | $299.76 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $286.45 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Janssen Biotech, INC. | $279.76 | 2020-2025 | Rybrevant, Darzalex |
| Celgene Corporation | $246.80 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $244.63 | 2020-2023 | Padcev, Tukysa, Adcetris |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $243.97 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $225.43 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $224.12 | 2019-2025 | Ninlaro, Iclusig, Vonvendi |
| Incyte Corporation | $221.47 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $194.18 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $175.86 | 2019-2023 | Imbruvica, Epkinly |
| Sobi, INC | $172.60 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $165.30 | 2019-2025 | Ultomiris |
| Gilead Sciences, INC. | $158.59 | 2022-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $151.56 | 2022-2025 | |
| Amgen INC. | $146.94 | 2021-2023 | Kyprolis, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $131.05 | 2021-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $130.76 | 2023-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $128.54 | 2021-2025 | |
| Puma Biotechnology, INC. | $125.14 | 2019-2025 | |
| Emd Serono, INC. | $115.71 | 2019-2025 | Bavencio |
| Blueprint Medicines Corporation | $95.67 | 2021-2025 | Ayvakit |
| Stemline Therapeutics INC. | $93.76 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $85.15 | 2019-2024 | |
| Myovant Sciences INC. | $81.69 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $78.86 | 2021-2025 | Myrisk, Endopredict |
| Genmab U.S., INC. | $71.85 | 2022-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $71.80 | 2021-2025 | Onivyde, Tazverik |
| Servier Pharmaceuticals LLC | $69.99 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $64.60 | 2019-2024 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.27 | 2021-2025 | Gilotrif |
| Beigene USA, INC. | $61.59 | 2020-2024 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $57.81 | 2022-2024 | Yonsa, Odomzo |
| Mirati Therapeutics, INC. | $54.62 | 2023-2024 | Krazati |
| Teva Pharmaceuticals USA, INC. | $53.26 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $51.39 | 2025 | Monoferric |
| Pharmaessentia USA Corporation | $50.00 | 2022-2024 | Besremi |
| Novocure INC. | $48.87 | 2019 | |
| Epizyme, INC. | $46.80 | 2020-2021 | |
| Kyowa Kirin, INC. | $46.45 | 2022-2024 | Poteligeo |
| Tersera Therapeutics LLC | $45.93 | 2021-2024 | Zoladex |
| Tg Therapeutics, INC. | $40.40 | 2022 | |
| Cti Biopharma Corp. | $37.57 | 2022-2023 | Vonjo |
| G1 Therapeutics, INC. | $36.91 | 2022-2023 | Cosela |
| Karyopharm Therapeutics INC. | $34.52 | 2021-2024 | Xpovio |
| Dendreon Pharmaceuticals LLC | $34.23 | 2019-2025 | Provenge |
| Beone Medicines USA, INC. | $31.86 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Tempus Ai, INC | $24.47 | 2025 | Xt Cdx |
| Dova Pharmaceuticals | $24.26 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $24.11 | 2021 | |
| Progenics Pharmaceuticals, INC. | $23.68 | 2025 | |
| Verastem, INC. | $23.67 | 2019 | |
| Cycle Pharmaceuticals INC | $23.09 | 2025 | Phyrago |
| Cvrx, INC. | $20.69 | 2024 | Barostim Neo System |
| Coherus Oncology, INC. | $19.78 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.64 | 2021 | |
| Mylan Institutional INC. | $19.16 | 2023 | Ogivri, Fulphila |
| Advanced Accelerator Applications | $18.73 | 2020 | |
| Legend Biotech USA INC. | $18.48 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $18.36 | 2024 | Clonoseq |
| Tesaro, INC. | $17.84 | 2019 | |
| Telix Pharmaceuticals | $17.46 | 2025 | Illuccix |
| Accord Healthcare, INC. | $17.17 | 2023 | |
| Aveo Pharmaceuticals, INC. | $15.21 | 2021 | |
| Forte Bio-Pharma LLC | $14.79 | 2022 | |
| Exelixis INC. | $10.91 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
Kisqali $1,444Ibrance $596Enhertu $356Keytruda $291Lenvima $265Orgovyx $205Braftovi $187Mektovi $187Epkinly $185Lorbrena $177Padcev $170Xalkori $156Doptelet $154Adcetris $153Sarclisa $151Imbruvica $147Tukysa $144Lynparza $135Opdivo $133Xtandi $129Jaypirca $117Verzenio $117Rybrevant $115Pluvicto $114Retevmo $109Nubeqa $103Venclexta $102Ojjaara $102Ninlaro $97.58Orserdu $93.76Elrexfio $91.90Ultomiris $89.02Eliquis $87.46Reblozyl $86.25Lunsumio $86.00Imfinzi $85.74Xofigo $85.69Jakafi $83.44Polivy $81.20Libtayo $74.33Talzenna $71.60Trodelvy $64.83Columvi $63.65Monjuvi $61.80Zejula $56.45Jemperli $56.45Paxlovid $55.48Krazati $54.62Brukinsa $51.47Monoferric $51.39Bosulif $50.15Welireg $49.84Tavalisse $47.94Rezlidhia $47.94Lutathera $46.15Pomalyst $43.40Iclusig $43.37Ayvakit $42.60Zynlonta $40.63Vitrakvi $40.21Stivarga $40.21Yonsa $39.36Odomzo $39.36Besremi $36.88Vonvendi $34.94Illuccix $34.92Poteligeo $33.22Inqovi $32.54Lonsurf $32.54Onivyde $31.68Myrisk $31.16Zoladex $30.96Tazverik $30.09Alecensa $29.05Tecentriq $29.05Phesgo $29.05Gilotrif $26.85Kyprolis $26.83Darzalex $25.95Xt Cdx $24.47Promacta $24.23Zynyz $24.09Pylarify $23.68Phyrago $23.09Comirnaty $22.46Zepzelca $22.09Ziihera $21.59Itovebi $21.03Provenge $21.00Barostim Neo System $20.69Fabhalta $20.45Bavencio $20.32Vyloy $20.27Xpovio $20.19Hympavzi $20.16Cosela $20.14Inlyta $19.36Fulphila $19.16Ogivri $19.16Carvykti $18.48
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Chohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.